734 search results for “targeted therapy” in the Public website
-
and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists
Source: Org Biomol Chem, Volume 13, Issue 8, pp. 2407-22 (2015)
-
Cevdet Acarsoy
Faculteit der Sociale Wetenschappen
c.acarsoy@fsw.leidenuniv.nl | +31 71 527 2727
-
Rethinking antibiotic therapy of urinary tract infections
Suruchi Nepal, postdoc in the group of Coen van Hasselt at LACDR, was awarded an NWO XS project which aims to study the response to antibiotic treatment during a urinary tract infection (UTI). This knowledge will be used to determine how treatments of UTIs with antibiotics can be further improved.
-
'Art therapy effective in treating anxiety in women'
On 22 January, Annemarie Madani-Abbing will defend her dissertation 'Art therapy and anxiety' regarding her research into the effectiveness of anthroposophic art therapy in treating anxiety in women. We asked her about her research and what it was like to combine a job outside academia with studying…
-
New cell therapy facility at Leiden Bio Science Park
American pharmaceutical company Bristol Myers Squibb will be building a new (CAR-T) cell therapy facility in the Oegstgeest part of the Leiden Bio Science Park. The company will manufacture and develop CAR T-cell therapy for patients with blood cancer (leukaemia), for example.
-
the regional and sectoral levels and projections in light of policy targets
Has the industrial sector in China effectively been decarbonizing in recent years, across different regions and subsectors, and is it plausible that it will reduce its CO2 emissions in conformity with national and internationally pledged emission goals?
-
Translational Immuno-Pharmacology
The Translational Immuno-Pharmacology group works on translating the efficacy of anti-infective therapy from preclinical (e.g. in vivo) to clinical, and is led by Rob van Wijk. Infectious diseases, such as tuberculosis, are in constant need of new therapies that work better, faster, and with less risk…
-
LUMC signs international agreement on developing Advanced Therapy Medicinal Products
Skåne University Hospital, Lund University and Leiden University Medical Center will work together to expand their research, teaching and development relating to Advanced Therapy Medicinal Products. That is the essence of a Memorandum of Understanding signed at SciLifeLab near Stockholm on Wednesday…
-
Special nanoparticles for cancer therapy! Will you help?
Developing a better treatment for patients with head and neck cancer, that is what Binanox, The 2022 iGEM Leiden team, want to achieve. They hope to raise at least 10,000 euros for this cause. Support their crowdfunding campaign today.
-
Unlocking the potential of small molecules in cancer therapy
How can we translate more fundamental discoveries into clinical solutions for patients? From that question, the Oncode Accelerator programme emerged. Professor of Molecular Physiology Mario van der Stelt has been one of the driving forces behind it since its inception. In an interview on the website…
-
The NKG2A / HLA-E axis a novel target for immune checkpoint therapy
PhD defence
-
Antiviral Pharmacology
The focus of the Antiviral Pharmacology group led by Anne-Grete Märtson is optimizing antiviral therapy for different viral infections by conducting clinical trials and using innovative computational and dynamic laboratory methodologies.
-
‘Take medicine target saturation into account’
Not taking into account the saturation of drug targets can lead to wrong conclusions about the duration of a drug's action. This is what former PhD candidate Wilbert de Witte writes together with the Leiden professors of pharmacology Meindert Danhof, Piet van der Graaf, and Liesbeth de Lange in Nature…
-
Building blocks of success
A research into for whom, when and why the Cool Little Kids intervention works.
-
Targeting recidivism
On Thursday 26 January 2017 Anouk Bosma will defend her doctoral thesis ‘Targeting recidivism: An evaluation study into the functioning and effectiveness of a prison-based treatment program’. The defence will start at 15.00 hrs, at the Academy Building of Leiden University, Rapenburg 73. Supervisor…
-
Erik Danen appointed as Professor of Cancer drug target discovery
As of April 1, 2018, Erik Danen has been appointed as Professor of Cancer drug target discovery at the Leiden Academic Centre for Drug Research (LACDR). His discipline is cell biology of cancer, in which he focuses on the mechanisms underlying metastasis and therapy resistance.
-
X-ray mirrors: useful in space, but also for radiation therapy
A special type of mirror to reflect X-rays has more possible applications than space research. Targeted radiation therapy for cancer, for example. Next to his full-time job, physicist David Girou mapped out the possibilities. He will receive his PhD on 14 June.
-
Prediction of brain target site concentrations on the basis of CSF PK: impact of mechanisms of blood-to-brain transport and within brain distribution
Promotor: Prof.dr. M. Danhof, Co-promotor: E.C.M. de Lange
-
Drug Discovery & Safety
In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.
-
LUMC will administer first Dutch stem cell gene therapy to patients
Researchers and clinicians at Leiden University Medical Centre (LUMC) are about to begin a milestone clinical study. It will be the first time a stem cell gene therapy developed in the Netherlands is used in a clinic. The therapy will be used to treat children with SCID, a rare disorder where children…
-
Facing your fears together
Peer-mentored cognitive behavioral therapy for adolescents with mild intellectual disability and anxiety disorder
-
Master’s programme in Transfusion Medicine and Cellular and Tissue Therapies
LUMC and Leiden University will start the new two-year online master's program in Transfusion Medicine and Cellular and Tissue Therapies from October 2023.
-
patient in the Netherlands successfully treated with stem cell gene therapy
Researchers from the Leiden University Medical Center (LUMC) have successfully used stem cell gene therapy to treat a baby with the severe congenital immune disorder SCID. An important milestone: it is the first time stem cell gene therapy of Dutch origin has been administered to a patient, and also…
-
The @school project
Developmental considerations in the design and delivery of cognitive-behavioural therapy for adolescent school refusal
-
Exposure therapy also helps patients with childhood trauma process the past
Childhood trauma can have a lifelong effect. Many therapists do not dare to confront these vulnerable patients with their past because they are concerned that the patients will be unable to cope. Research has now shown that exposure therapy can be helpful for this group of people.
-
‘How can we translate the language of cells into cancer therapies?’
On 23 April 2021, Professor Alfred Vertegaal from the Department of Cell and Chemical Biology at the Leiden University Medical Center (LUMC) delivered his inaugural lecture ‘Unraveling and exploiting cellular communication codes’. Vertegaal used the opportunity to describe how research in the field…
-
Targeting for success: Mechanistic insights into microRNA-based gene therapy for Huntington disease
PhD defence
-
Challenged by cognition
Toward optimal measurement and greater understanding of youth cognition in school refusal and cognitive behavioural therapy outcome
-
Medicine/Leiden University Medical Center
We are very happy to welcome you to spend a semester or year studying or doing an internship with us at the Leiden University Medical Center. Here you will find information on your course timetables and registration.
-
Tom van der Wel
Science
t.van.der.wel@lic.leidenuniv.nl | +31 71 527 3527
-
Danielle Oprel
Faculteit der Sociale Wetenschappen
d.a.c.oprel@fsw.leidenuniv.nl | +31 71 527 2727
-
Femke Stad
Faculteit der Sociale Wetenschappen
f.e.stad@fsw.leidenuniv.nl | +31 71 527 6790
-
Rianne de Kleine
Faculteit der Sociale Wetenschappen
r.a.de.kleine@fsw.leidenuniv.nl | +31 71 527 5435
-
Marike Kooistra
Faculteit der Sociale Wetenschappen
m.j.kooistra@fsw.leidenuniv.nl | +31 71 527 1726
-
Katja Cardol
Faculteit der Sociale Wetenschappen
c.k.cardol@fsw.leidenuniv.nl | +31 71 527 5697
-
Phyto-pharmaceuticals and gene targeting
We exploit secondary metabolites of plant to develop pharmaceutical compounds and we genetically modify plant genomes to improve crops.
-
The Metallophilic Interaction between Cyclometalated Complexes: Photobiological Applications
In this thesis, the researcher developed a nanosystem based on the metallophilic Interaction between cyclometalated complexes.
-
Discovery of BUB1 kinase inhibitors for the treatment of cancer
The spindle-assembly checkpoint (SAC) is a safety mechanism which secures accurate chromosome segregation during mitosis.
-
Targeting the immune system to inhibit atherosclerosis
A new treatment for atherosclerosis showed promising results in isolated cells but proved to be less effective in initial animal tests. Bachelor student Biopharmaceutical Sciences Willemijn van der Heijden aimed to understand why. She investigated whether the formation of a protein layer around the…
-
How bittersweet sugar chemistry targets pathogens
The challenge is considerable, but so is the satisfaction when it succeeds: creating complex sugar molecules that play a role in biology.
-
Jeanine de Roy van Zuijdewijn about the term ‘soft target’
Since the attack of 22 may 2017 in the Manchester Arena, we have often seen the term ‘soft target’. Jeanine de Roy van Zuijdewijn, researcher at the Institute of Security and Global Affairs, took part in a Q&A about the attack in Manchester.
-
Tessa Hagens
Science
t.m.s.hagens@lacdr.leidenuniv.nl | +31 71 527 5919
-
Adriaan IJzerman
Science
ijzerman@lacdr.leidenuniv.nl | +31 71 527 2727
-
Cancer Therapeutics and Drug Safety
In this research group, headed by Bob Van de Water, cell signaling programs that underlie adverse drug reactions as well as cancer development and progression are unraveled. Adverse drug reactions involve cell injury in critical target organ cells which leads to the activation of cellular stress response…
-
eLaw hosts Panel Discussion 'Online Targeted Advertising and Human Dignity'
eLaw is thrilled to let you know that on 29 April (17:00-19:00), we will be hosting Prof. Luciano Floridi, Prof. Brett Frischmann and Prof. Shoshana Zuboff on the online (zoom) panel discussion with the question – Should online targeted advertisement be banned on the premise that it violates human d…
-
Transnational Terrorism as a Threat: Cross-Border Threats
The authors detail the transnationality of terrorist organisations, including fundraising, communications, alliance-forming, movement and target selection.
-
Novel analytical approaches to characterize particles in biopharmaceuticals
Particles are omnipresent in biopharmaceutical products. In protein-based therapeutics such particles are generally associated with impurities, either derived from the drug product itself (e.g. protein aggregates), or from extrinsic contaminations (e.g. cellulose fibers).
-
Rowie Stolk on individual companies being targeted in test cases
Interest group Animal Rights has started a test case to prompt the Netherlands Food and Consumer Product Safety Authority (NVWA) to tackle farmers who do not adequately protect their livestock against wolves. The test case concerns a rejected enforcement request to the NVWA. In it, the NVWA were called…
-
Single-cell immune profiling of atherosclerosis: from omics to therapeutics
Acute cardiovascular syndromes, including myocardial infarction or stroke, are the principal cause of death in the Western society. The main underlying pathology of cardiovascular diseases is atherosclerosis, which is caused by the accumulation of lipids and inflammatory cells in the vessel wall, in…
-
NKI-AVL and LUMC are joining forces in immunotherapy
Strengthening a cancer patient's own immune system so that the body itself can better destroy cancer cells. This is at the heart of immunotherapy, the most promising progress in cancer treatment in recent years. In order to drive this development further, the Netherlands Cancer Institute-Antoni van…